Michael Mucha

Matrix Analytics, Inc. provides a powerful solution for identifying and managing cancer and incidental findings. The company is based in Glendale, CO. The company's EPM Pancreas solution tracks patients to aid in the early detection of pancreatic cancer by identifying incidental pancreatic cysts from radiology reports. Additionally, their software, EON, addresses the issue of less than 30% of incidental pulmonary nodules receiving follow-up care according to recommended guidelines. The company was founded in 2014 by Akrum Alzubaidi, who has been the CEO since 2014.

Matrix Analytics, Inc. provides a powerful solution for identifying and managing cancer and incidental findings. The company is based in Glendale, CO. The company's EPM Pancreas solution tracks patients to aid in the early detection of pancreatic cancer by identifying incidental pancreatic cysts from radiology reports. Additionally, their software, EON, addresses the issue of less than 30% of incidental pulmonary nodules receiving follow-up care according to recommended guidelines. The company was founded in 2014 by Akrum Alzubaidi, who has been the CEO since 2014.

Matrix Analytics, Inc. provides a powerful solution for identifying and managing cancer and incidental findings. The company is based in Glendale, CO. The company's EPM Pancreas solution tracks patients to aid in the early detection of pancreatic cancer by identifying incidental pancreatic cysts from radiology reports. Additionally, their software, EON, addresses the issue of less than 30% of incidental pulmonary nodules receiving follow-up care according to recommended guidelines. The company was founded in 2014 by Akrum Alzubaidi, who has been the CEO since 2014.

Matrix Analytics, Inc. provides a powerful solution for identifying and managing cancer and incidental findings. The company is based in Glendale, CO. The company's EPM Pancreas solution tracks patients to aid in the early detection of pancreatic cancer by identifying incidental pancreatic cysts from radiology reports. Additionally, their software, EON, addresses the issue of less than 30% of incidental pulmonary nodules receiving follow-up care according to recommended guidelines. The company was founded in 2014 by Akrum Alzubaidi, who has been the CEO since 2014.